Abreva and Therapeutic response unexpected - a phase IV clinical study of FDA data

Summary:

Therapeutic response unexpected is reported as a side effect among people who take Abreva (docosanol), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Erbitux, and have Oral herpes.

The phase IV clinical study analyzes which people have Therapeutic response unexpected when taking Abreva. It is created by eHealthMe based on reports of 17,058 people who have side effects when taking Abreva from the FDA, and is updated regularly.

What is Abreva?

Abreva has active ingredients of docosanol. It is often used in herpes labialis (oral herpes simplex). eHealthMe is studying from 17,071 Abreva users. Check the latest studies of Abreva.

What is Therapeutic response unexpected?

Therapeutic response unexpected is found to be associated with 1,418 drugs and 1,557 conditions by eHealthMe. Check the latest studies of Therapeutic response unexpected.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

17,058 people reported to have side effects when taking Abreva.
Among them, 40 people (0.23%) have Therapeutic response unexpected.

Could Abreva cause Therapeutic response unexpected?

Among these 40 people:

How long have people been on Abreva when they have Therapeutic response unexpected? *

What is the gender of people who have Therapeutic response unexpected when taking Abreva? *

female: 68.97 %
male: 31.03 %

What is the age of people who have Therapeutic response unexpected when taking Abreva? *

What are other drugs people take besides Abreva? *

Zovirax: 1 person, 2.50%
Valacyclovir: 1 person, 2.50%
Erbitux: 1 person, 2.50%

What are other side effects people have besides Therapeutic response unexpected? *

Drug Ineffective: 4 people, 10.00%
Pain: 1 person, 2.50%
Oral Herpes (viral infection of mouth): 1 person, 2.50%
Lip Pain: 1 person, 2.50%
Herpes Zoster: 1 person, 2.50%
Drug Administration Error: 1 person, 2.50%
Application Site Irritation: 1 person, 2.50%
Application Site Erythema (redness of the skin at application site): 1 person, 2.50%

What are the existing conditions these people have? *

Oral Herpes (viral infection of mouth): 16 people, 40.00%
Acne (skin problems that cause pimples): 4 people, 10.00%
Herpes Zoster: 3 people, 7.50%
Herpes Virus Infection: 2 people, 5.00%
Rashes (redness): 2 people, 5.00%
Bacterial Infection: 1 person, 2.50%
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 1 person, 2.50%
Cheilitis (infection of lips): 1 person, 2.50%
Cuts And Puncture Wounds: 1 person, 2.50%
Genital Herpes (herpes infection of genital): 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Abreva and have Therapeutic response unexpected?

- Check whether Therapeutic response unexpected is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abreva:

Abreva (17,071 reports)

Browse all side effects of Abreva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Therapeutic response unexpected:

Therapeutic response unexpected (1,418 drugs)

Browse all the conditions that are associated with Therapeutic response unexpected:

Therapeutic response unexpected (1,557 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on docosanol (the active ingredients of Abreva) and Abreva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.